<DOC>
	<DOCNO>NCT02745743</DOCNO>
	<brief_summary>The purpose study identify appropriate dose safely administered effect blood cancer cell . Once safe dose identify , additional patient ask join study evaluate safety effectiveness study drug . The study also investigate pharmacokinetics ( study body drug ) , well pharmacodynamics ( study drug body ) , may provide information effect BAY 1251152 . The study also measure biological marker ( marker biological activity body ) use predict response safety propose treatment .</brief_summary>
	<brief_title>Phase I Trial BAY1251152 Advanced Blood Cancers</brief_title>
	<detailed_description />
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Male female patient age ≥18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Life expectancy least 12 week Patients able willing provide bone marrow biopsies/aspirates request protocol Patients confirm advanced hematological malignancy Negative serum pregnancy test Women men reproductive potential must agree use highly effective contraception sexually active . Ability understand willingness sign write informed consent . Patients must adequate coagulation ( international normalize ratio ( INR ) prothrombin time ( PT ) , partial thromboplastin time ( PTT ) ≤1.5 time ULN ) Adequate liver function ( total bilirubin ≤ 1.5 time ULN , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 time ULN Presence active/uncontrolled central nervous system involvement History clinically significant cardiac disease ; uncontrolled hypertension Left ventricular ejection fraction ( LVEF ) &lt; 45 % Allogeneic stem cell transplant within 100 day first dose study drug Known history human immunodeficiency virus ( HIV ) infection Chronic active hepatitis B C , require antiviral therapy Evidence history bleed disorder , dialysis , coexist cancer distinct primary site histology cancer evaluate study Serious , uncontrolled infection Unresolved chronic toxicity &gt; grade 1 prior therapy Use strong CYP3A4 inhibitor strong inducer within 7 day prior start study treatment duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Dose expansion</keyword>
	<keyword>Positive transcription elongation factor b inhibitor</keyword>
	<keyword>Cyclin-dependent kinase 9 inhibitor</keyword>
</DOC>